(Q37006353)

17 August 2017

1 reference

title

Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications (English)

1 reference

17 August 2017

0 references

1 reference

Dirk J van Veldhuisen

series ordinal

5

object named as

Dirk J van Veldhuisen

1 reference

17 August 2017

2

Adriaan A Voors

1 reference

17 August 2017

Jasper W L Hartog

1

1 reference

PubMed ID

18023248

17 August 2017

Stephan J L Bakker

series ordinal

3

1 reference

PubMed ID

18023248

17 August 2017

Andries J Smit

series ordinal

4

1 reference

17 August 2017

1 December 2007

1 reference

European Journal of Heart Failure

17 August 2017

1 reference

17 August 2017

9

1 reference

17 August 2017

1146-1155

1 reference

17 August 2017

12

1 reference

The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT S

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Skin autofluorescence is a strong predictor of cardiac mortality in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

New developments in the pharmacological treatment of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Accumulation of Maillard reaction products in skin collagen in diabetes and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Tobacco smoke is a source of toxic reactive glycation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Role of oxidized low density lipoprotein in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

The role of nitric oxide synthase/nitric oxide in vascular smooth muscle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Aminoguanidine prevents age-related deterioration in left ventricular-arterial coupling in Fisher 344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Advanced glycation end products: sparking the development of diabetic vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.009

10.1016/J.EJHEART.2007.09.009

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18023248